The vast majority of funding for biological research in the US comes from the National Institutes of Health (NIH), and as a result, most of our grants are written in a way that plays up the clinical importance of our work. Some variant of the phrase,

This research has implications in the treatment/prevention of [insert disease here]…

appears in just about every grant and research paper in my field. In truth, it’s often very difficult to draw a direct line between a specific research project and a drug that your doctor can prescribe. We like to pretend that we can leverage research to develop drugs in a rational way, but honestly, a lot of treatments are discovered by accident, and then we go back and try to figure out why they work.

My favorite exception to this principal is the drug Natalizumab (trade name Tysabri), which was designed to treat the autoimmune disease multiple sclerosis and turned out to be remarkably effective. Before I explain how the drug works, some background:

Multiple sclerosis (MS) is an autoimmune disorder in which a patient’s immune system goes after the cells in their central nervous system – the spinal cord and brain. As with most autoimmune disorders, we’re not really sure how it gets started, but once the immune system decides that it wants to attack something, the process is relentless. The symptoms vary widely depending on which areas of the brain are attacked – everything from loss of coordination and balance to paralysis, loss of vision/hearing and loss of speech – and the disease is typically progressive, meaning that symptoms build and compound over time as more and more of the brain is destroyed.

In other words, it sucks. Hard.

If caught early, there are a number of treatments that can slow the progression of the disease, but as with most autoimmune, disorders, most therapies are not specific. We know MS is caused largely by T-cells, and we know plenty about how T-cells work. There are drugs that will readily kill off your T-cells. Unfortunately, you need your T-cells to fight off the myriad of infectious organisms that you come into contact with every day, so treating MS with those drugs would likely lead to rapid death by virus. There’s very little that we know about that distinguishes a T-cell that’s attacking your brain from a T-cell that’s attacking the flu

As with other autoimmune diseases, we can use other drugs that suppress the immune system generally, but these can’t be used to completely block the immune response – again, because you’re immune system is important for other reasons – so this strategy can only slow down the inevitable (and even at low doses, these drugs will make you more susceptible to infectious diseases).

Hopefully, you now understand the nature of the problem. How can you block the immune response in MS without blocking all the other immune responses that your body needs? I mentioned that there isn’t much that distinguishes the T-cells causing MS from all the other T-cells in your body, but there is at least one: MS-causing T-cells need to get to the brain. A couple of weeks ago, I wrote about how the cells of the immune system navigate the body, using a set of molecules called selectins, chemokines and integrins as a sort of “area code” that determines where T-cells and other white blood cells go in order to do their job.

Natalizumab, the drug I mentioned at the top, is a direct result of the research on cell migration. Instead of trying to destroy the T-cells directly, scientists realized that we could just screw up their targeting systems. Natalizumab blocks the α4 integrin, which T-cells need in order stop in the blood stream at a place where they can enter the brain.

<iframe width=”420″ height=”315″ src=”http://www.youtube.com/embed/yChFz3_td4A” frameborder=”0″ allowfullscreen></iframe>

They just roll on by, and since they’re programed to attack things that are only found in the brain, these T-cells can keep on circulating throughout the body without causing problems. In addition, because α4 integrin is specific to the brain and the gut, this drug doesn’t screw up all of your normal T-cells. If you have a virus infection in your lungs or a bacterial infection in your toe, the T-cells responding recognize different integrins, so they function just fine.

Of course, there are some downsides to Natalizumab. It’s a monoclonal antibody – a huge protein rather than a small molecule. Functionally, this means that you can’t take it in pill form (your stomach acid would bust it up), so patients need to go to a doctor every month and get an infusion. Not only is this a hassle, it also means that the treatment is quite expensive (though on the bright side, autoimmunity isn’t that big a problem in the developing world) Also, there’s a reason T-cells evolved a way to get into the brain in the first place: you can get infections in the brain, and need T-cells to help deal with them. Natalizumab has indeed been linked to some fatal viral infections in the brain.

Still, for people suffering from MS, or newly diagnosed, this treatment is an amazing advance – and it’s a direct result of the understanding gained from basic research.

 

Comments

  1. #1 Mike Cummings
    June 6, 2012

    Thanks for posting this. I have MS and am being treated with Tysabri. As you say, MS sucks hard. My monthly treatments are expensive and inconvenient, but there are few side effects, and that’s a big selling point, because for most MS patients, the side effects from the other drugs are almost as bad as the disease.
    But I appreciate your explanation of how natalizumab works. Most literature either dumbs it down to the point of uselessness or is so technical it’s only comprehensible to specialists.

    • #2 Kevin Bonham
      June 6, 2012

      You’re welcome :-).

  2. #3 Saurabh Chowdhry
    Bayside,NY
    June 7, 2012

    An absolutely great post. I have MS and take Tysabri. Indeed, relative to the side effects of other MS drug therapies, Tysabri has next to none. I have to agree that this is the major selling point. Your description of the manner in which Tysabri works is very clear and easy to understand for the layman. All in all, great job on this!!

  3. #4 Rafael Science
    Brazil
    June 8, 2012

    I am not sure that medical students are familiar with all this molecular pathways. The more information is available, the more important is to student to learn molecular biology and genetics. The process of learning on different dimensions (macro,micro, nano) is hard but in the future will certainly safe many lives

    Thanks for the post

  4. #5 Connor
    United Kingdom
    June 10, 2012

    Nice post, I didn’t know of this exception. It’s actually pretty inspiring to see, despite some the downsides. Do you know of any next-generation treatments based on this?

    • #6 Kevin Bonham
      June 10, 2012

      There are a number of new drugs based on the idea of using antibodies to block things (any drug named something-MAB), like rituxumab that’s used to treat B-cell lymphomas. I’m not aware of anyone doing research on small-molecule drugs that would work to block cell migration, but this isn’t really my field so it’s entirely possible.

  5. #7 Michael
    Melbourne, Austrlia
    June 12, 2012

    Kevin,If as your blog suggests “leveraging immunology to treat disease” is true, then why are all the newest treatments for autoimmune conditions designed to silence or shutdown the immune response? Would you ever suggest that the constant work being done by the immune system be tampered with? Never. Why? Because if it were so, you would argue that infection (viral, bacterial, fungal, exogenous etc.) would be so widespread that it would kill the host. So it follows that a immunosupressed host would also suffer invasion from opportunistic and persistent pathogens . Yet all current autoimmune treatments are based on shutting down the only form of defence the host has to ongoing pathogenic infection. I understand that ongoing chronic inflammation is damaging to the host and that shutting down the inflammation caused by autoimmune responses halts symptoms from worsening, but it does not arrest progression of the condition, it actually increases and changes the co-morbidity of symptoms experienced by the host. I have always believed in the maxim “Attack is the best form of defence”. In fact, that is what the Human immune system is predicated on. I suggest, as your blog proclaims, that leveraging the immune system to treat disease, is in fact what researchers should be focussing on. New treatments should be aimed at stimulating immune pathways to assist them in eliminating opportunistic pathogens and their deleterious impact on host inflammation and health.

    • #8 Kevin Bonham
      June 21, 2012

      @ Michael – Sorry for the delay in approving your comment and my response.

      We suppress the immune system to treat autoimmunity because it’s the least bad option. Untreated autoimmunity gets bad faster than when it’s treated (as you mentioned). You’re right to say that the immunosuppression can lead to co-morbidity with opportunistic infections, and that it’s in no way ideal. However, autoimmune disorders left unchecked are way worse and lead to pain and death far more quickly. My own grandmother died in the hospital of a bacterial infection that she likely would have been able to combat had she not been on so many anti-inflammatory arthritis meds. However, the 10 years of her life up until that point would have been lived in excruciating pain if not for those meds.

      Ideally, we would be able to suppress only those parts of the immune system that are actually over-reacting during autoimmunity, or we’d be able to enhance the regulatory immune cells that normally prevent autoimmunity, or we’d figure out why the immune system over reacts in the first place. People are working hard on those problems, and hopefully one day we’ll get there. But we’re not there yet.

  6. #9 megan
    June 28, 2012

    interesting post.
    any thoughts on dr. terry wahls approach?

    http://www.youtube.com/watch?v=KLjgBLwH3Wc